US FDA Inspection In Store? Here Are Some Areas That May Be On Agency’s Radar
Executive Summary
Risks like highly manual aseptic filling lines, poor root cause investigations and unwritten procedures were examined in Mumbai workshop.
You may also be interested in...
Facing Regulatory Heat, Indian Pharma Turns To Quality Solutions
Against a backdrop of US FDA warnings and global regulatory convergence, the Indian pharma industry is looking to build in quality from project inception and foster an unbiased approach to quality across global markets, a conference in Mumbai hears.
The Next New Thing In FDA Inspections: Poor Root Cause Investigations
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.